Pharmaceuticals
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific...
2026-09-28 10:05
3600
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabo...
2026-09-28 08:00
2419
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
--- In a large China real-world study of 281 heavily pretreated, predominantly high-risk patients with relapsed/refractory plasma cell neoplasms,FUCASO achieved a 95.9% objective response rate, a 77.2% CR/sCR rate, and a 94.1% MRD negativity rate --- with median PFS and OS not yet reached (12-mo...
2026-09-27 11:16
2654
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in a popula...
2026-09-27 11:03
7986
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch cli...
2026-09-25 20:00
9753
Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters
* The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships. * The move is part of Lundbeck's continued investment in the US, a key market, and will support the company's Focused In...
2026-09-25 15:52
3201
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
* This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's AI and robotics-driven drug discovery platform and its transition to a clinical-stage organization. * Preclinical data demonstrate sub-nanomol...
2026-09-25 08:30
3992
Basecamp Research raises $140M to advance AI-designed therapeutics
/C O R R E C T I O N -- Basecamp Research/ In the news release, Basecamp Research raises $140M to advance AI-designed therapeutics, issued 23-Sep-2026 by Basecamp Research over PR Newswire, we are advised by the company that information has changed in the first bulleted subheadline and in the fo...
2026-09-25 01:44
2603
Strategic Collaboration | Sanyou Bio and NovoCodex Partner to Co-Develop Innovative Dual-Payload ADCs
SHANGHAI and SHAOXING, China, Sept. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointlyannounced that the two companies have formally entered into a strategic collaboration agreement. The partnership will foc...
2026-09-24 22:00
4245
Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology
WILMINGTON, Del., Sept. 24, 2026 /PRNewswire/ -- Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs ...
2026-09-24 19:00
1964
Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
* 104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion * Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 * First-in-class PRS inhibitor being developed as a potential new therapeutic option...
2026-09-24 08:00
2788
Basecamp Research raises $140M to advance AI-designed therapeutics
* Oversubscribed Series C led by S32 with backing from NVIDIA and others * Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships * The company has demonstrated strong preclinical results across multiple modal...
2026-09-23 21:00
1204
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
FDA Clearance and CE Mark Complete Aptiva's Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Werfen today announced that its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin A (IgA) Reagent has received both ...
2026-09-23 20:00
1541
HKSH Medical Group and United Imaging Mark Launch of Hong Kong's First Long-Axial PET/CT
HONG KONG, Sept. 23, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) and United Imaging Healthcare (United Imaging) announced on September 23 the arrival of Hong Kong's first long-axial PET/CT, the uMI Panorama GS, at HKSH Cancer Centre, providing a new technology platform for molecular imaging cl...
2026-09-23 18:30
1280
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2026-09-23 16:48
1612
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
* Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. * Expansion Opportunity Beyond Dercum's Disease—Study findings support the potential development of CBL-514 for Lipedema...
2026-09-23 10:08
1473
Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. * Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2...
2026-09-23 10:05
3041
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
* Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. * Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. ...
2026-09-23 01:36
985
Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies
BEIJING, Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput screening, ...
2026-09-22 22:22
851
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and
Triggers $2 Million Payment to Kazia
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
2026-09-22 19:30
2240
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
24889